Report Description of the EU SGLT2 Inhibitor Market Analysis
Research Scope and Assumption
- The report provides the market value for the base year 2020 and a yearly forecast up to 2028 in terms of revenue (USD billion)
- The key industry dynamics, regulatory scenario, reimbursement scenario, major market trends, and drug markets are evaluated to understand their impacts on the demand for the forecast period. The growth rates were estimated using correlation, regression, and time-series analysis
- We have used the combination of top-down and bottom-up approach for market sizing, analyzing key regional markets, dynamics, and trends for various solutions, services, and end uses
- All market estimates and forecasts have been validated through primary interviews with the Key Industry Players (KIPs) and secondary analysis
- Inflation has not been accounted for in order to estimate and forecast the market
- Numbers may not add up due to rounding off
Reason to buy the report:
- Facilitate decision-making based on strong current and forecast data for EU SGLT2 Inhibitor Market Analysis
- Develop strategies based on the latest regulatory framework
- Strategically analyze micro-markets with respect to individual growth trends, future prospects, and their contribution to the market
- Analyze competitive developments such as expansions, investments, mergers & acquisitions, new product developments, and research & developments in the EU SGLT2 Inhibitor Market Analysis
- Analyze the opportunities in the market for stakeholders and draw a competitive landscape for market leaders
- To strategically profile key players and comprehensively analyze their market shares and core competencies
- We have technically sound team which do a deep dive research and also provide strategy based consulting analysis
EU SGLT2 Inhibitor Market Analysis Executive Summary
SGLT2 inhibition effectively lowers blood glucose levels and also accords other benefits, such as weight loss, low incidence of hypoglycaemia, and reduction in blood pressure. SGLT2 inhibitor is the newest addition into the armamentarium to treat Type-2 Diabetes. Kidney plays a very important role in glucose homeostasis by regulating gluconeogenesis, glucose uptake from the circulation, and glucose reabsorption from the urine filtered in the renal glomeruli.
Market Size and Key Findings
The EU SGLT2 Inhibitor Market Analysis size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of 17% during the forecast period.
The size of the SGLT2 Inhibitor Market in the Europe is predicted to be growing at a CAGR of 17% from 2021 to 2028.
Market Dynamics
Market Growth Drivers Analysis
The exponential growth of diabetic population YoY, especially type 2 diabetic patients, new innovative drugs are coming up in the market to increase the ease of access to the patients. With the increase in diabetic population, the need and demand for diabetes drugs are expected to increase. The other factors, such as better adoption than other therapies and government initiatives, are driving the diabetes drugs market.
Market Restraints
The older patient group and clinical inertia are the main barriers to initiate SGLT2i for eligible patients. Clinicians should change the glucocentric approach and focus on reducing renal events in T2D.
Competitive Landscape
Key Players
Company Coverage: –
- Eli Lilly
- Janssen Pharmaceuticals
- Boehringer Ingelheim
- AstraZeneca
- Bristol Myers Squibb
Products in Pipeline
- A handful of SGLT2 inhibitors have been approved for the treatment of type 2 diabetes or are currently undergoing clinical trials. Currently there are three SGLT2 selective inhibitors approved by the Food and Drug Administration (FDA) for mono, dual, and triple therapy: canagliflozin (Invokana®), dapagliflozin (Farxiga®) and empagliflozin (Jardiance®)
Notable Recent Deals
EU approval should give AZ and BMS first-to-market advantage over other companies developing SGLT2 inhibitors, notably Johnson & Johnson’s canagliflozin and Boehringer Ingelheim/Eli Lilly’s empagliflozin. Canagliflozin was filed for approval in the US in June, while empagliflozin is scheduled for regulatory submissions during 2013.
Healthcare Policies and Regulatory Landscape
Policy changes and Reimbursement scenario
On 25 February 2016, the European Medicines Agency (EMA) confirmed recommendations1 to minimise the risk of diabetic ketoacidosis in patients taking SGLT2 inhibitors (a class of type 2 diabetes medicines).
Diabetic ketoacidosis is a serious complication of diabetes caused by low insulin levels. Rare cases of this condition, including life-threatening ones, have occurred in patients taking SGLT2 inhibitors for type 2 diabetes and a number of these cases have been atypical, with patients not having blood sugar levels as high as expected.
An atypical presentation of diabetic ketoacidosis can delay diagnosis and treatment. Healthcare professionals should therefore consider the possibility of ketoacidosis in patients taking SGLT2 inhibitors who have symptoms consistent with the condition even if blood sugar levels are not high.
Following a review of the cases, EMA recommended updating the product information of SGLT2 inhibitors to list diabetic ketoacidosis as a rare adverse reaction (affecting up to 1 in 1,000 patients).
Patients taking these medicines should be aware of the symptoms of diabetic ketoacidosis, including rapid weight loss, nausea or vomiting, stomach pain, excessive thirst, fast and deep breathing, confusion, unusual sleepiness or tiredness, a sweet smell to the breath, a sweet or metallic taste in the mouth, or a different odour to urine or sweat. Patients should contact a doctor or the nearest hospital straightaway if they have any of these symptoms.
If diabetic ketoacidosis is suspected or confirmed, treatment with SGLT2 inhibitors should be stopped immediately and should not be re-started unless another cause for the ketoacidosis is identified and resolved.
Healthcare professionals should exercise caution with SGLT2 inhibitors in patients with risk factors for ketoacidosis and inform patients of these factors. These include low insulin-producing capacity in the pancreas, a sudden drop in a patient’s insulin dose, increased insulin requirement (due to illness, surgery or alcohol abuse) or conditions that can restrict food intake or lead to severe dehydration.
